跳至主要内容
临床试验/NCT04340219
NCT04340219已完成不适用

A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)

University Hospital, Ghent1 个研究点 分布在 1 个国家目标入组 394 人开始时间: 2020年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
394
试验地点
1
主要终点
Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression); in terms of proportions (0-4 vs ≥ 5).

研究概览

简要总结

ONCOVID is a prospective cohort study investigating oncology-patient-reported anxiety, mood, and quality of life during the COVID-19 pandemic. Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (COVID-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, and WHO Quality of Life-BREF). Data collection occurs at baseline and follow-up surveys are performed after 6, 12, and 24 weeks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years of age
  • Histologically confirmed cancer
  • Receive systemic therapy (including chemotherapy, targeted small-molecule therapy, anticancer monoclonal antibody, immunotherapy, endocrine therapy, or investigational agent) (either exclusively or in combination with other anticancer therapy) between February 14, 2020 and March 31, 2020 (Note: Patients whose systemic treatment administration was initially planned for this period but was modified, delayed, stopped, or withheld due to COVID-19 measures are also eligible for inclusion)

排除标准

  • Insufficient understanding of the Dutch language
  • Severe cognitive impairment
  • Acute psychiatric crisis
  • Not able to give informed consent
  • Confirmed or clinically suspected COVID-19
  • Endocrine therapy in (neo)adjuvant setting (Note: Patients whose (neo)adjuvant systemic treatment was initially planned as chemotherapy, targeted small-molecule therapy, anticancer monoclonal antibody, immunotherapy, or investigational agent (either exclusively or in combination in combination with other anticancer therapy) but was modified to endocrine therapy due to COVID-19 measures are also eligible for inclusion)

结局指标

主要结局

Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression); in terms of proportions (0-4 vs ≥ 5).

时间窗: Week 0

Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21-Stress); in terms of proportions (0-7 vs ≥ 8).

时间窗: Week 0

Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs ≥ 29).

时间窗: Week 0

Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21-Anxiety); in terms of proportions (0-3 vs ≥ 4).

时间窗: Week 0

次要结局

  • Depression at baseline measured by the DASS-21-Depression; in terms of continuous values.(Week 0)
  • Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Social relationships); in terms of continuous values.(Week 0)
  • Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Psychological health); in terms of continuous values.(Week 0)
  • Change from baseline in distress measured by CDPI; in terms of continuous values.(24 weeks)
  • Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Physical health; in terms of continuous values.(24 weeks)
  • Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Social relationship; in terms of continuous values.(24 weeks)
  • Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF-Environment; in terms of continuous values.(24 weeks)
  • Distress measured at baseline by the CPDI; in terms of continuous values.(Week 0)
  • Stress at baseline measured by the DASS-21-Stress; in terms of continuous values.(Week 0)
  • Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF-Physical health); in terms of continuous values.(Week 0)
  • Change from baseline in stress measured by the DASS-21-Stress; in terms of continuous values.(24 weeks)
  • Anxiety at baseline measured by the DASS-21-Anxiety; in terms of continuous values.(Week 0)
  • Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF-Psychological health; in terms of continuous values.(24 weeks)
  • The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics(Week 0-6-12-24)
  • Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF-Environment); in terms of continuous values.(Week 0)
  • Change from baseline in depression measured by the DASS-21-Depression; in terms of continuous values.(24 weeks)
  • Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire-in terms of continuous values.(Week 0)
  • Change from baseline in anxiety measured by the DASS-21-Anxiety; in terms of continues values.(24 weeks)
  • Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.(24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Oncology-patient-reported Anxiety, Mood, and QoL... | 临床试验